Charles River Laboratories International Financial Statements ()
|
|
|
|
Report date
|
|
|
11.02.2020 |
17.02.2021 |
16.02.2022 |
22.02.2023 |
14.02.2024 |
|
06.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
2 621 |
2 924 |
3 540 |
3 976 |
4 129 |
|
4 061 |
|
Operating Income, bln rub |
|
|
351.2 |
432.7 |
589.9 |
651.0 |
617.3 |
|
562.9 |
|
EBITDA, bln rub |
? |
|
581.7 |
759.1 |
854.3 |
1 036 |
1 032 |
|
990.4 |
|
Net profit, bln rub |
? |
|
252.0 |
364.3 |
391.0 |
486.2 |
474.6 |
|
413.1 |
|
|
OCF, bln rub |
? |
|
480.9 |
546.6 |
760.8 |
619.6 |
683.9 |
|
796.2 |
|
CAPEX, bln rub |
? |
|
140.5 |
166.6 |
228.8 |
324.7 |
318.5 |
|
235.7 |
|
FCF, bln rub |
? |
|
340.4 |
380.0 |
532.0 |
294.9 |
365.4 |
|
560.5 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
607.2 |
640.8 |
744.8 |
811.7 |
885.3 |
|
773.4 |
|
Cost of production, bln rub |
|
|
1 663 |
1 850 |
2 206 |
2 513 |
2 627 |
|
2 692 |
|
R&D, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Interest expenses, bln rub |
|
|
60.9 |
86.4 |
73.9 |
59.3 |
136.7 |
|
131.6 |
|
|
Assets, bln rub |
|
|
4 693 |
5 491 |
7 024 |
7 603 |
8 195 |
|
8 004 |
|
Net Assets, bln rub |
? |
|
1 635 |
2 115 |
2 535 |
2 976 |
3 597 |
|
3 782 |
|
Debt, bln rub |
|
|
2 004 |
2 135 |
2 919 |
3 097 |
3 066 |
|
2 759 |
|
Cash, bln rub |
|
|
238.0 |
228.4 |
241.2 |
233.9 |
276.8 |
|
210.2 |
|
Net debt, bln rub |
|
|
1 766 |
1 907 |
2 678 |
2 863 |
2 790 |
|
2 549 |
|
|
Ordinary share price, rub |
|
|
151.9 |
251.7 |
369.2 |
217.9 |
236.4 |
|
198.3 |
|
Number of ordinary shares, mln |
|
|
48.7 |
49.6 |
50.3 |
50.8 |
51.2 |
|
51.4 |
|
|
Market cap, bln rub |
|
|
7 404 |
12 472 |
18 568 |
11 072 |
12 110 |
|
10 192 |
|
EV, bln rub |
? |
|
9 170 |
14 379 |
21 246 |
13 935 |
14 900 |
|
12 741 |
|
Book value, bln rub |
|
|
-595 |
-482 |
-1 238 |
-829 |
-362 |
|
-121 |
|
|
EPS, rub |
? |
|
5.17 |
7.35 |
7.77 |
9.57 |
9.27 |
|
8.04 |
|
FCF/share, rub |
|
|
6.99 |
7.67 |
10.6 |
5.80 |
7.13 |
|
10.9 |
|
BV/share, rub |
|
|
-12.2 |
-9.73 |
-24.6 |
-16.3 |
-7.07 |
|
-2.35 |
|
|
EBITDA margin, % |
? |
|
22.2% |
26.0% |
24.1% |
26.1% |
25.0% |
|
24.4% |
|
Net margin, % |
? |
|
9.61% |
12.5% |
11.0% |
12.2% |
11.5% |
|
10.2% |
|
FCF yield, % |
? |
|
4.60% |
3.05% |
2.87% |
2.66% |
3.02% |
|
5.50% |
|
ROE, % |
? |
|
15.4% |
17.2% |
15.4% |
16.3% |
13.2% |
|
10.9% |
|
ROA, % |
? |
|
5.37% |
6.63% |
5.57% |
6.40% |
5.79% |
|
5.16% |
|
|
P/E |
? |
|
29.4 |
34.2 |
47.5 |
22.8 |
25.5 |
|
24.7 |
|
P/FCF |
|
|
21.7 |
32.8 |
34.9 |
37.5 |
33.1 |
|
18.2 |
|
P/S |
? |
|
2.82 |
4.27 |
5.25 |
2.78 |
2.93 |
|
2.51 |
|
P/BV |
? |
|
-12.4 |
-25.9 |
-15.0 |
-13.4 |
-33.4 |
|
-84.4 |
|
EV/EBITDA |
? |
|
15.8 |
18.9 |
24.9 |
13.5 |
14.4 |
|
12.9 |
|
Debt/EBITDA |
|
|
3.04 |
2.51 |
3.13 |
2.76 |
2.70 |
|
2.57 |
|
|
R&D/CAPEX, % |
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
CAPEX/Revenue, % |
|
|
5.36% |
5.70% |
6.46% |
8.17% |
7.71% |
|
5.80% |
|
| Charles River Laboratories International shareholders |
